Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: Connection refused in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa preis

besponsa preis

Перейти к контенту

Главное меню:

Разное
besponsa preis
Welcome to BESPONSA® | BESPONSA®, EU nod for Pfizer’s Besponsa - PharmaTimes, BESPONSA® Approved in the EU for Adult Patients with , FDA Approves Besponsa (Inotuzumab Ozogamicin) for Acute , Besponsa for Acute Lymphoblastic Leukemia Approved by FDA, Besponsa Market (2019-2025) by Growth | Pfizer - openPR, , , .
BESPONSA can cause liver problems that can be severe, life-threatening, or fatal, including a condition called veno-occlusive disease (VOD). This condition can occur during treatment with BESPONSA or following subsequent treatment with a stem cell transplant. This condition was more common in patients who had elevated liver tests or who received dual alkylating agents in preparation for their stem cell transplant. Patients may be at a higher risk of VOD if they: . BESPONSA is a prescription medicine used to treat adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). It is not known if BESPONSA is safe and effective in children under 18 years of age.. Pfizer’s antibody drug conjugate Besponsa has become the first to be approved by regulators in Europe to treat some adults with the rare, aggressive cancer acute lymphoblastic leukaemia (ALL). The decision allows the drug’s use for relapsed or refractory CD22-positive ALL in patients who have.
BESPONSA is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody (mAb) targeting CD22, a cell surface antigen expressed on cancer cells in almost all B-ALL patients, linked to a cytotoxic agent.8 When BESPONSA binds to the CD22 antigen on B-cells, it is internalized into the cell, where the cytotoxic agent calicheamicin is released to destroy the cell.9 . BESPONSA originates . Besponsa is a kind of targeted therapy called an antibody-drug conjugate, a monoclonal antibody linked to a chemotherapy drug. It’s thought to work by attaching to B-cell ALL cancer cells that express the CD22 protein, blocking the growth of cancer cells. It is intended to target and kill only the cancer cells and spare healthy cells.. Besponsa is a CD22-antibody therapy that functions by binding to the ALL cancer cells that display the CD22 antigen on their surface. Through this binding, the drug initiates a response which resulting in the attenuation of growth of these cancer cells.. The report on the global Besponsa market is comprehensively prepared with main focus on the competitive landscape, geographical growth, segmentation, and market dynamics, including drivers . . .
 
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню